GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Enhancing triple negative breast cancer response to immune checkpoint inhibitor therapy via targeted therapies

$7,461
Kennady Bullock · Vanderbilt University · F31 · FY2024 · CA

Cyclin-dependent kinase control of cell-division and transcription cycles

$7,332
Robert P Fisher · Icahn School Of Medicine At Mount Sinai · R35 · FY2021 · GM

Checkpoints of TNF Gene Regulation

$7,290
Anne Goldfeld · Boston Children'S Hospital · R01 · FY2014 · GM

Clinical Investigations and Precision Therapeutics

$7,153
Janice M. Mehnert · Rbhs -Cancer Institute Of New Jersey · P30 · FY2019 · CA

SPINDLE CHECKPOINT SIGNALING

$7,064
Kevin S Hardwick · University Of Washington · P41 · FY2010 · RR

Mechanism of Immune Dysfunction and Morbid Outcomes in Response to Shock/Sepsis

$7,057
Alfred Ayala · Rhode Island Hospital · R35 · FY2024 · GM

Durvalumab in Combination with Olaparib in Non-Small Cell Lung Cancer

$7,024
Arun Rajan · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA

2020 DNA Damage, Mutation and Cancer GRC/GRS

$7,000
Hannah L Klein · Gordon Research Conferences · R13 · FY2020 · CA

Cancer Immunology Program - 03

$6,864
Drew M. Pardoll · Johns Hopkins University · P30 · FY2018 · CA

Breast and Ovarian Cancer Program - 08

$6,863
Vered Stearns · Johns Hopkins University · P30 · FY2018 · CA

Live cell reporters of genetic changes in stiff vs soft surroundings - Causes & Consequences

$6,689
Dennis E. Discher · University Of Pennsylvania · U01 · FY2024 · CA

Applying deep learning to predict T cell receptor binding specificity of neoantigens and response to checkpoint inhibitors

$6,465
Tao Wang · Ut Southwestern Medical Center · R01 · FY2023 · CA

Cancer Cell Biology and Signaling Research Program

$6,313
Vivek M Rangnekar · University Of Kentucky · P30 · FY2018 · CA

Program 30: Neuro-Oncology

$6,168
Charles Stiles · Dana-Farber Cancer Inst · P30 · FY2019 · CA

Program 4: Leukemia

$6,168
Benjamin Levine Ebert · Dana-Farber Cancer Inst · P30 · FY2019 · CA

Innate and Non-Classical Immune Cells in Cancer Immunotherapy

$6,000
Thale Cross Jarvis · Keystone Symposia · R13 · FY2019 · CA

Role of melanoma-PD-1 in cancer progression

$5,903
Tobias Schatton · Brigham And Women'S Hospital · R01 · FY2019 · CA

Program 4: Leukemia

$5,849
Benjamin Levine Ebert · Dana-Farber Cancer Inst · P30 · FY2018 · CA

Program 30: Neuro-Oncology

$5,848
Charles Stiles · Dana-Farber Cancer Inst · P30 · FY2018 · CA

Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer

$5,840
Alice Berger · Fred Hutchinson Cancer Center · R37 · FY2024 · CA

Signaling and Biotechology Program

$5,639
Hui-Kuan Lin · Wake Forest University Health Sciences · P30 · FY2019 · CA

25 Cancer Genetics and Epigenetics

$5,456
Sharon R Dent · University Of Tx Md Anderson Can Ctr · P30 · FY2019 · CA

07 Gastrointestinal Cancers

$5,456
Scott Kopetz · University Of Tx Md Anderson Can Ctr · P30 · FY2019 · CA

11 Prostate Cancer

$5,455
Christopher J. Logothetis · University Of Tx Md Anderson Can Ctr · P30 · FY2019 · CA

Immunology and Cancer Immunotherapy (ICI)

$5,263
Mary J Turk · Dartmouth College · P30 · FY2024 · CA